T细胞急性淋巴细胞白血病中CD38的多模态分析确定联合治疗策略
该研究通过多模态分析儿童T-ALL样本,揭示了CD38的表达异质性、调控因子及与多胺代谢和炎症信号通路的关联,并提出了CD38靶向治疗与DFMO或达沙替尼联合的合理策略。
要点
- CD38在T-ALL中广泛表达,但表达水平随基因组和免疫表型亚型而异。
- CD38缺失下调IL32表达,提示其与炎症信号通路相关。
- CD38与LCK正相关,达雷妥尤单抗联合达沙替尼可改善生存。
核心结论
- CD38在T-ALL中与可靶向通路和基因存在先前未认识的相互作用,联合策略可增强CD38靶向治疗并降低复发风险。
研究设计与样本
- 对儿童T-ALL样本进行多模态分析,包括1335例原发肿瘤的bulk RNA测序、150例原发样本的流式细胞术和40例的CITE测序。
主要发现
- CD38表达在基因组和免疫表型亚型间存在差异,但表面广泛表达。
- CRISPR筛选鉴定RUNX1、RUNX3和TP53为CD38的候选正调控因子。
- CD38扰动后多胺通路紊乱,DFMO联合靶向CD38改善临床前模型生存。
- CD38缺失或阴性时IL32表达一致下降,提示与炎症信号通路关联。
- CD38与LCK表达在多数基因组亚型中正相关,达沙替尼联合达雷妥尤单抗改善生存优于单药。
临床怎么用
- 可考虑将CD38靶向治疗与多胺代谢 disruptor DFMO或SRC激酶抑制剂达沙替尼联合用于T-ALL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes for pediatric patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) are poor, underscoring the need for improved therapeutic strategies. CD38, a type II transmembrane glycoprotein, is a promising target in T-ALL, with clinical trials evaluating CD38-targeting immunotherapies in frontline and relapsed settings. However, the biological role of CD38 in T-ALL has not been systematically defined. We interrogated CD38 biology through multimodal profiling of pediatric T-ALL samples. Bulk RNA sequencing of 1,335 primary tumors revealed that CD38 expression varies across genomic and immunophenotypic subtypes in T-ALL. Flow cytometry of 150 primary samples and CITE-sequencing of 40 cases demonstrated broad surface expression of CD38. A transcription factor CRISPR-screen identified RUNX1, RUNX3, and TP53 as candidate positive regulators of CD38. Metabolomic profiling of cell lines further revealed disruption of the polyamine pathway following CD38 perturbation. Supporting this finding, co-targeting CD38 with difluoromethylornithine (DFMO), a polyamine metabolism disruptor, improved survival in preclinical models. Across transcriptomic datasets, including primary tumors, cell lines, and patient-derived xenograft models, IL32 expression consistently decreased following CD38 loss or negativity, supporting an association between CD38 and inflammatory signaling pathways. Additionally, CD38 and LCK expression were positively correlated across majority of genomic subtypes, implicating SRC kinase signaling. Consistent with this, daratumumab in cell lines increased LCK phosphorylation, and combination therapy with dasatinib improved survival compared to monotherapy. Collectively, these findings define previously unrecognized interactions between CD38 and targetable pathways and genes in T-ALL and identify rational combinatorial strategies to enhance CD38-directed therapies and reduce relapse risk.
引用
- Shraim R, Shi G, Li Y, et al. Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies. Blood. 2026. PMID: 42685004. doi:10.1182/blood.2026034575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。